Exenatide vs SHLP2

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Exenatide

Exenatide was the first GLP-1 receptor agonist approved in the US, derived from a compound found in Gila monster saliva. Available as Byetta (twice daily) and Bydureon (once weekly extended-release).

Full details →

SHLP2

SHLP2 (Small Humanin-Like Peptide 2) is a mitochondrial-derived peptide similar to humanin. It has shown insulin-sensitizing and cytoprotective effects in research, with potential metabolic benefits.

Full details →

Side-by-Side Comparison

Aspect	Exenatide	SHLP2
Dose Range	5 mcg–10 mcg	1 mg–5 mg
Frequency	2x daily	1x daily
Cycle Length	8–24 weeks	4–8 weeks
Route	subcutaneous	subcutaneous
Mechanism	Synthetic version of exendin-4, which activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety.	Enhances insulin sensitivity and glucose uptake. Provides cytoprotective effects similar to humanin. May act through similar but distinct receptor pathways.
Typical Dosage	Byetta: 5mcg twice daily for 1 month, then 10mcg twice daily. Bydureon: 2mg subcutaneously once weekly.	Research compound with doses in the microgram to low milligram range studied in animal models. Human dosing not established.
Administration	Byetta: Inject within 60 minutes before morning and evening meals. Bydureon: Any time of day, with or without meals. Do not mix with insulin in same syringe.	Subcutaneous or intraperitoneal injection in research settings. Various SHLP analogs (1-6) have different properties.
Side Effects	Nausea (especially initially), vomiting, diarrhea, dizziness, headache, and injection site reactions (particularly with Bydureon).	Limited data. Animal studies suggest good tolerability. May affect glucose metabolism.
Best For	Fat Loss	Fat Loss Anti-Aging & Longevity